Denise K Walters
Overview
Explore the profile of Denise K Walters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walters D, Jelinek D
J Histochem Cytochem
. 2024 Jul;
72(7):435-451.
PMID: 39054649
Hematopoietic and stromal cells within the bone marrow (BM) provide membrane-bound and/or soluble factors that are vital for the survival of plasma cells (PCs). Recent reports in murine BM demonstrated...
2.
Hoelzinger D, Quinton S, Walters D, Vardam-Kaur T, Tschumper R, Borges da Silva H, et al.
Blood Adv
. 2022 Apr;
6(11):3458-3471.
PMID: 35395072
Identifying factors secreted by multiple myeloma (MM) cells that may contribute to MM tumor biology and progression is of the utmost importance. In this study, hepatoma-derived growth factor (HDGF) was...
3.
Tschumper R, Hoelzinger D, Walters D, Davila J, Osborne C, Jelinek D
Noncoding RNA
. 2022 Feb;
8(1).
PMID: 35202088
The differentiation of B cells into antibody secreting plasma cells (PCs) is governed by a strict regulatory network that results in expression of specific transcriptomes along the activation continuum. In...
4.
Sakemura R, Hefazi M, Siegler E, Cox M, Larson D, Hansen M, et al.
Blood
. 2022 Jan;
139(26):3708-3721.
PMID: 35090171
Pivotal clinical trials of B-cell maturation antigen-targeted chimeric antigen receptor T (CART)-cell therapy in patients with relapsed/refractory multiple myeloma (MM) resulted in remarkable initial responses, which led to a recent...
5.
Walters D, Jelinek D
J Histochem Cytochem
. 2019 Dec;
68(2):99-112.
PMID: 31855110
The ability to visualize and quantify the spatial arrangement and geographic proximity of immune cells with tumor cells provides valuable insight into the complex mechanisms underlying cancer biology and progression....
6.
Sterner R, Sakemura R, Cox M, Yang N, Khadka R, Forsman C, et al.
Blood
. 2018 Nov;
133(7):697-709.
PMID: 30463995
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. These include cytokine release syndrome (CRS) and...
7.
Walters D, Arendt B, Tschumper R, Wu X, Jelinek D
Exp Hematol
. 2017 Oct;
57:42-49.e1.
PMID: 29030084
The genetic abnormalities underlying multiple myeloma (MM) are notoriously complex and intraclonal heterogeneity is a common disease feature. In the current study, we describe the establishment of a monoclonal immunoglobulin...
8.
Arendt B, Walters D, Wu X, Tschumper R, Jelinek D
Oncotarget
. 2014 Jul;
5(14):5686-99.
PMID: 25015330
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells within the bone marrow. There is a growing literature that tumor cells release biologically active microvesicles (MVs)...
9.
Walters D, Arendt B, Jelinek D
Cell Cycle
. 2013 Sep;
12(19):3175-83.
PMID: 24013424
Increased use of the glycolytic pathway, even in the presence of oxygen, has recently been recognized as a key characteristic of malignant cells. However, the glycolytic phenotype results in increased...
10.
Greenberg A, Walters D, Kumar S, Rajkumar S, Jelinek D
Eur J Haematol
. 2013 Sep;
91(6):504-13.
PMID: 23992230
The introduction of novel immunomodulatory drugs (IMiDs) has dramatically improved the survival of patients with multiple myeloma (MM). While it has been shown that patients with specific cytogenetic subtypes, namely...